FDA Grants Clearance to Allergan’s TrueTear, the First Intranasal Neurostimulating Device

Allergan has received FDA marketing clearance for its TrueTear intranasal tear neurostimulator, which was developed to temporarily increase tear production during neurostimulation in adult patients.

The handheld device is a non-invasive and drug-free stimulator with daily disposable tips that is inserted into the nasal cavity to induce the production of tears.

Two clinical studies showed positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients. — Cynthia Jessup